IXHL
Incannex Healthcare Limited
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · AU
$3.26
+0.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 66.6K | 86.0K | 12.0K | — | 785.2K |
| Cost of Revenue | 179.8K | 246.0K | 103.0K | — | 6.3K |
| Gross Profit | (128.4K) | (160.0K) | 12.0K | — | 778.8K |
| Operating Expenses | |||||
| R&D Expense | 14.7M | 10.7M | 19.3M | 9.5M | 5.4M |
| SG&A Expense | 20.2M | 13.1M | 25.6M | 11.9M | 10.2M |
| General & Admin Expense | 20.2M | 12.7M | 24.0M | 10.0M | 7.4M |
| Selling & Marketing Expense | — | 390.0K | 1.6M | 1.9M | 2.7M |
| Other Expenses | (233.0K) | (246.0K) | (14.8M) | (895.5K) | (3.4M) |
| Total Operating Expenses | 34.7M | 23.6M | 30.1M | 20.5M | 12.1M |
| Cost and Expenses | 34.9M | 23.9M | 30.1M | 20.5M | 12.2M |
| Operating Income (EBIT) | (34.8M) | (23.8M) | (30.0M) | (20.5M) | (11.4M) |
| Non-Operating | |||||
| Interest Income | 49.0K | 62.0K | 308.4K | 362.7K | 6.3K |
| Interest Expense | 264.0K | 303.0K | — | — | — |
| Net Interest Income | (215.0K) | (241.0K) | 308.4K | 362.7K | 6.3K |
| Other Non-Op Income/Expense | (24.2M) | (24.9M) | 178.0K | (52.9M) | (3.6M) |
| Non-Operating Income (excl Interest) | (1.5M) | — | — | — | — |
| EBT (Pre-Tax Income) | (59.0M) | (48.6M) | (18.4M) | (73.5M) | (14.9M) |
| Income Tax Expense | — | (1.8M) | 30.0K | — | — |
| Bottom Line | |||||
| Net Income | (49.9M) | (46.9M) | (18.5M) | (73.5M) | (14.9M) |
| Earnings from Cont. Ops | (49.9M) | (46.9M) | (18.5M) | (73.5M) | (14.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (49.9M) | (46.9M) | (18.5M) | (73.5M) | (14.9M) |
| Per Share | |||||
| Basic EPS | ($2.24) | ($40.80) | ($3.42) | ($14.31) | ($1.50) |
| Diluted EPS | ($2.24) | ($40.80) | ($3.42) | ($14.31) | ($1.50) |
| Revenue Per Share | $0.01 | $0.07 | $0.00 | $0.00 | $0.08 |
| Shares | |||||
| Basic Shares Outstanding | 12.3M | 1.1M | 5.4M | 5.1M | 9.9M |
| Diluted Shares Outstanding | 12.3M | 1.1M | 5.4M | 5.1M | 9.9M |
| Profitability Metrics | |||||
| EBITDA | (53.2M) | (23.5M) | (27.7M) | (20.4M) | (16.5M) |
| D&A | 96.5K | 246.0K | 154.2K | 132.4K | 11.4M |
| EBIT | (53.3M) | (23.8M) | (27.9M) | (20.5M) | (16.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026